---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-21T23:47:02.114465'
end_time: '2025-12-21T23:52:01.470584'
duration_seconds: 299.36
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: LPCAT2
  gene_symbol: LPCAT2
  uniprot_accession: Q7L5N7
  protein_description: 'RecName: Full=Lysophosphatidylcholine acyltransferase 2; Short=LPC
    acyltransferase 2; Short=LPCAT-2; Short=LysoPC acyltransferase 2; EC=2.3.1.23
    {ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase
    11; Short=1-AGP acyltransferase 11; Short=1-AGPAT 11; EC=2.3.1.51 {ECO:0000269|PubMed:20363836};
    AltName: Full=1-acylglycerophosphocholine O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine
    O-acyltransferase; EC=2.3.1.25 {ECO:0000250|UniProtKB:Q8BYI6}; AltName: Full=1-alkylglycerophosphocholine
    O-acetyltransferase; EC=2.3.1.67 {ECO:0000269|PubMed:17182612}; AltName: Full=Acetyl-CoA:lyso-platelet-activating
    factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF
    acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 1; AltName:
    Full=Lysophosphatidic acid acyltransferase alpha; Short=LPAAT-alpha;'
  gene_info: Name=LPCAT2; Synonyms=AGPAT11, AYTL1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the 1-acyl-sn-glycerol-3-phosphate
  protein_domains: EF-hand-dom_pair. (IPR011992); EF_Hand_1_Ca_BS. (IPR018247); EF_hand_dom.
    (IPR002048); LPCAT1-like. (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q7L5N7
- **Protein Description:** RecName: Full=Lysophosphatidylcholine acyltransferase 2; Short=LPC acyltransferase 2; Short=LPCAT-2; Short=LysoPC acyltransferase 2; EC=2.3.1.23 {ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase 11; Short=1-AGP acyltransferase 11; Short=1-AGPAT 11; EC=2.3.1.51 {ECO:0000269|PubMed:20363836}; AltName: Full=1-acylglycerophosphocholine O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase; EC=2.3.1.25 {ECO:0000250|UniProtKB:Q8BYI6}; AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase; EC=2.3.1.67 {ECO:0000269|PubMed:17182612}; AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 1; AltName: Full=Lysophosphatidic acid acyltransferase alpha; Short=LPAAT-alpha;
- **Gene Information:** Name=LPCAT2; Synonyms=AGPAT11, AYTL1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 1-acyl-sn-glycerol-3-phosphate
- **Key Domains:** EF-hand-dom_pair. (IPR011992); EF_Hand_1_Ca_BS. (IPR018247); EF_hand_dom. (IPR002048); LPCAT1-like. (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LPCAT2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LPCAT2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LPCAT2** (gene ID: LPCAT2, UniProt: Q7L5N7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q7L5N7
- **Protein Description:** RecName: Full=Lysophosphatidylcholine acyltransferase 2; Short=LPC acyltransferase 2; Short=LPCAT-2; Short=LysoPC acyltransferase 2; EC=2.3.1.23 {ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase 11; Short=1-AGP acyltransferase 11; Short=1-AGPAT 11; EC=2.3.1.51 {ECO:0000269|PubMed:20363836}; AltName: Full=1-acylglycerophosphocholine O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase; EC=2.3.1.25 {ECO:0000250|UniProtKB:Q8BYI6}; AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase; EC=2.3.1.67 {ECO:0000269|PubMed:17182612}; AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 1; AltName: Full=Lysophosphatidic acid acyltransferase alpha; Short=LPAAT-alpha;
- **Gene Information:** Name=LPCAT2; Synonyms=AGPAT11, AYTL1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 1-acyl-sn-glycerol-3-phosphate
- **Key Domains:** EF-hand-dom_pair. (IPR011992); EF_Hand_1_Ca_BS. (IPR018247); EF_hand_dom. (IPR002048); LPCAT1-like. (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LPCAT2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LPCAT2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LPCAT2** (gene ID: LPCAT2, UniProt: Q7L5N7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan (concise)
- Verify identity and nomenclature: LPCAT2 (UniProt Q7L5N7), human, aliases AGPAT11/AYTL1; LPCAT family with EF-hand–related annotations in UniProt. (Verification completed.)
- Compile recent primary studies/reviews (2023–2024) plus key mechanistic classics on enzymatic function, specificity, localization, and regulation; extract quantitative/statistical data. (Completed.)
- Map roles in biochemical pathways (Lands’ cycle; PAF biosynthesis; inflammatory lipid mediator/eicosanoid context) and disease-relevant mechanisms (cancer, immunity, differentiation). (Completed.)
- Synthesize current applications/analysis and expert perspectives. (Completed.)
- Write comprehensive, well-cited report with URLs and publication dates. (Completed.)

Comprehensive research report: Human LPCAT2 (UniProt Q7L5N7)

Identity verification and nomenclature
- Gene/protein: Lysophosphatidylcholine acyltransferase 2 (LPCAT2), synonyms AGPAT11, AYTL1; human enzyme in the LPCAT/LPLAT family. This matches the user-supplied UniProt identity and aliases. (wang2019phospholipidremodelingin pages 28-28, shindou2009recentprogresson pages 4-5)
- Organism: Homo sapiens. Mechanistic and localization data below include human experimental evidence; several classic functional insights derive from mouse macrophages but are conserved and widely cited. (wang2019phospholipidremodelingin pages 28-28, shindou2009recentprogresson pages 3-4)
- Family/domains: Member of AGPAT/LPLAT superfamily, often annotated with EF-hand–related motifs and regulatory Ca2+-responsiveness at the activity level. (shindou2009recentprogresson pages 4-5, shindou2009recentprogresson pages 3-4)

Key concepts and definitions (current understanding)
- Primary biochemical role: LPCAT2 is a lysophospholipid acyltransferase that reacylates lysophosphatidylcholine (lysoPC) at sn-2 using acyl‑CoA, contributing to Lands’ cycle phosphatidylcholine (PC) remodeling. It also functions as a lyso-PAF acetyltransferase (lysoPAFAT) that acetylates lyso‑PAF using acetyl‑CoA to generate platelet-activating factor (PAF), especially in inflammatory cells. This dual activity underlies its inducible role in inflammation versus constitutive membrane remodeling. (shindou2009recentprogresson pages 4-5, shindou2009recentprogresson pages 3-4, wang2019phospholipidremodelingin pages 28-28)
- Inducible vs constitutive paradigm: LPCAT2 is typically inducible/inflammatory, analogous to COX‑2, whereas LPCAT1 is constitutive, analogous to COX‑1. (shindou2009recentprogresson pages 4-5)

Enzymatic functions, reactions, and substrate specificity
- Reactions:
  • LPLAT/LPCAT reaction: lysoPC + acyl‑CoA → PC + CoA‑SH (sn‑2 reacylation in Lands’ cycle). (shindou2009recentprogresson pages 4-5)
  • Lyso‑PAF acetyltransferase: lyso‑PAF + acetyl‑CoA → PAF + CoA‑SH (inducible PAF biosynthesis in macrophages). (shindou2009recentprogresson pages 4-5, shindou2009recentprogresson pages 3-4, wang2019phospholipidremodelingin pages 28-28)
- Substrate specificity (evidence-based):
  • LPC species: Acts on lysoPC within remodeling and on lyso‑PAF within PAF synthesis. (shindou2009recentprogresson pages 4-5, shindou2009recentprogresson pages 3-4)
  • Acyl‑CoA preferences: Family literature emphasizes PUFA incorporation at sn‑2, including arachidonoyl‑CoA, though LPCAT isoform preferences vary; LPCAT2 has been reported as an LPLAT with lysoPC activity and inducible lyso‑PAF acetylation. Targeted 2024 differentiation studies assayed LPCAT activity with 16:0, 18:1, 18:2, 20:4 (arachidonoyl‑CoA), and 22:6 acyl‑CoAs in vitro, supporting use of common physiological acyl donors in cell systems. (tabe2024theroleof pages 3-5)
  • Reviews summarizing LPCAT2 indicate lysoPC/lysoPS acceptance and potential preference for oleoyl‑CoA in some contexts; these are review-level inferences. (korbecki2024phospholipidacyltransferasescharacterization pages 8-9)

Subcellular localization and structural/biophysical features
- Localization: Human LPCAT2 localizes to the endoplasmic reticulum and to lipid droplets (LDs). In mammalian cells, 10–30% of total LPCAT2 floated with LD fractions in sucrose gradients, with the remainder in membranes; both LPCAT1/2 showed dual ER/LD localization. This supports local PC synthesis on LD surfaces. (moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5)
- Topology: LPCAT2 is a monotopic membrane protein with a long hydrophobic segment enabling insertion into the LD phospholipid monolayer. (moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5)

Regulation and domains
- Ca2+ dependence and signaling: LPCAT2 activity is Ca2+-dependent (contrasting LPCAT1), and its lyso‑PAF acetyltransferase activity is acutely activated by LPS via a p38 MAPK–dependent pathway in macrophages; dexamethasone suppresses LPS‑induced LPCAT2 mRNA upregulation. These findings establish LPCAT2 as an inducible inflammatory enzyme. (shindou2009recentprogresson pages 3-4)

Pathways and biochemical context
- Lands’ cycle (PC remodeling): LPCAT2 contributes to reacylation of lysoPC to remodel membrane PC composition at sn‑2, shaping membrane properties and lipid mediator pools. (shindou2009recentprogresson pages 4-5)
- PAF biosynthesis: In inflammatory cells, LPCAT2 catalyzes lyso‑PAF acetylation to form PAF, providing a mechanism to couple membrane remodeling and rapid bioactive lipid production during TLR4 stimulation. (shindou2009recentprogresson pages 3-4, wang2019phospholipidremodelingin pages 28-28)
- Downstream inflammatory lipid mediator milieu: Inducible PAF production via LPCAT2 interfaces with eicosanoid-producing pathways in activated immune cells, as part of broader inflammatory lipid remodeling. (shindou2009recentprogresson pages 4-5)

Recent developments (2023–2024) and latest research
- 2024—Osteoblastic differentiation: In C2C12 cells, LPCAT2 mRNA and protein increased during osteoblastic differentiation; siRNA knockdown of LPCAT2 reduced osteoblastic markers (e.g., ALP, Col1) and decreased lipid droplet number/size, with statistical significance (ANOVA/t‑test, P < 0.05). Activity assays evaluated incorporation from multiple acyl‑CoAs including arachidonoyl‑CoA. These data implicate LPCAT2 in BMP/Smad signaling and osteoblastogenesis via lipid remodeling. (Published Jul 2024; https://doi.org/10.1002/2211-5463.13845) (tabe2024theroleof pages 3-5)
- 2024—Broad acyltransferase review: A comprehensive 2024 review summarizes LPCAT/AGPAT roles in membrane remodeling and disease, noting LPCAT2’s associations with inflammation and cancer; it aggregates survival correlations across cancers and mechanistic links to LD biology. As a review, it synthesizes earlier primary literature and should be interpreted accordingly. (Published May 2024; https://doi.org/10.3390/cancers16112115) (korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 8-9)

Current applications and real-world implementations
- Cancer lipid metabolism and chemoresistance: LPCAT2-driven lipid droplet biogenesis in colorectal cancer cells supports resistance to 5‑fluorouracil and oxaliplatin by dampening ER-stress–linked death pathways and limiting immunogenic cell death. Genetic manipulation of LPCAT2 modulates LD content and drug sensitivity in vitro and in mouse models, suggesting LPCAT2/LD-targeting strategies to resensitize tumors. (Published Jan 2018; https://doi.org/10.1038/s41467-017-02732-5) (wang2019phospholipidremodelingin pages 16-17)
- Immune/inflammatory signaling: In macrophage models, LPS acutely activates LPCAT2 lyso‑PAF acetyltransferase activity via p38 MAPK, linking TLR4 signaling to PAF production; dexamethasone suppresses LPS-induced LPCAT2 expression. These mechanistic axes connect LPCAT2 to real-world contexts like infection and sepsis biology. (Published Apr 2009; https://doi.org/10.1194/jlr.r800035-jlr200) (shindou2009recentprogresson pages 3-4)

Expert opinions and analysis
- Authoritative review perspective: LPCAT family enzymes, including LPCAT2, are central to phospholipid remodeling and pathophysiology; LPCAT2 is specifically highlighted in cancer contexts (chemoresistance, tumor progression) and in inducible inflammatory lipid mediator production, though mechanistic links to disease require further in vivo validation and selective chemical probes. (Published Feb 2019; https://doi.org/10.1146/annurev-physiol-020518-114444) (wang2019phospholipidremodelingin pages 16-17)

Relevant statistics and quantitative data
- Subcellular partitioning: In human cell lines, 10–30% of endogenous LPCAT2 floated with lipid droplet fractions on sucrose gradients, with the remainder in membrane/bottom fractions; both ER and LD localization are observed microscopically. (Published Jun 2011; https://doi.org/10.1074/jbc.M110.202424) (moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5)
- Differentiation model metrics: During C2C12 osteoblastic differentiation, ALP staining/activity increased by day 7 and LPCAT2 knockdown significantly reduced ALP and Col1 expression and decreased LD number/size (P < 0.05; multiple tests), implicating LPCAT2 functionally in osteoblastogenesis. (Published Jul 2024; https://doi.org/10.1002/2211-5463.13845) (tabe2024theroleof pages 3-5)

Disease associations and translational relevance (selected)
- Colorectal cancer: Elevated LPCAT2 associates with lipid droplet accumulation and chemoresistance; experimental modulation alters response to 5‑FU/oxaliplatin in vitro and in vivo, pointing to LPCAT2 as a druggable node in tumor lipid metabolism. (wang2019phospholipidremodelingin pages 16-17)
- Inflammation/innate immunity: TLR4–p38–LPCAT2 axis controls inducible PAF production; glucocorticoids suppress inducible expression, aligning LPCAT2 with anti-inflammatory pharmacology. (shindou2009recentprogresson pages 3-4)
- Differentiation and bone biology: LPCAT2 supports osteoblastic differentiation in C2C12 cells, potentially linking lipid remodeling, LD dynamics, and BMP/Smad signaling in osteogenesis. (tabe2024theroleof pages 3-5)

Limitations and open questions
- Isoform-specific substrate preferences and kinetics in human primary cells remain incompletely defined; detailed enzymology (kcat/Km by acyl‑CoA and lysoPC species) and structural basis for Ca2+ regulation merit updated investigation in 2023–2025 primary studies. (shindou2009recentprogresson pages 4-5, wang2019phospholipidremodelingin pages 16-17)
- Selective, in vivo–validated LPCAT2 inhibitors suitable for clinical translation are still needed to probe causality in inflammation and cancer.

Conclusion
Human LPCAT2 (Q7L5N7) is an inducible lysophospholipid acyltransferase at the ER and lipid droplets that couples Lands’ cycle PC remodeling with lyso‑PAF acetyltransferase activity for PAF biosynthesis. Its Ca2+‑dependent, p38‑MAPK–linked activation in macrophages anchors a role in inflammatory signaling, while its control of lipid droplet PC synthesis connects it to cancer chemoresistance and to differentiation programs sensitive to membrane lipid composition. Emerging 2024 data extend LPCAT2 biology to osteoblastic differentiation, underscoring LPCAT2 as a regulator of cell fate and stress responses through lipid remodeling. (shindou2009recentprogresson pages 3-4, wang2019phospholipidremodelingin pages 28-28, moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5, tabe2024theroleof pages 3-5, wang2019phospholipidremodelingin pages 16-17, shindou2009recentprogresson pages 4-5)

References

1. (wang2019phospholipidremodelingin pages 28-28): Bo Wang and Peter Tontonoz. Phospholipid remodeling in physiology and disease. Annual review of physiology, 81:165-188, Feb 2019. URL: https://doi.org/10.1146/annurev-physiol-020518-114444, doi:10.1146/annurev-physiol-020518-114444. This article has 481 citations and is from a highest quality peer-reviewed journal.

2. (shindou2009recentprogresson pages 4-5): Hideo Shindou, Daisuke Hishikawa, Takeshi Harayama, Koichi Yuki, and Takao Shimizu. Recent progress on acyl coa: lysophospholipid acyltransferase research. Journal of Lipid Research, 50:S46-S51, Apr 2009. URL: https://doi.org/10.1194/jlr.r800035-jlr200, doi:10.1194/jlr.r800035-jlr200. This article has 340 citations and is from a peer-reviewed journal.

3. (shindou2009recentprogresson pages 3-4): Hideo Shindou, Daisuke Hishikawa, Takeshi Harayama, Koichi Yuki, and Takao Shimizu. Recent progress on acyl coa: lysophospholipid acyltransferase research. Journal of Lipid Research, 50:S46-S51, Apr 2009. URL: https://doi.org/10.1194/jlr.r800035-jlr200, doi:10.1194/jlr.r800035-jlr200. This article has 340 citations and is from a peer-reviewed journal.

4. (tabe2024theroleof pages 3-5): Shirou Tabe, Hisako Hikiji, Tomomi Hashidate‐Yoshida, Hideo Shindou, Takao Shimizu, and Kazuhiro Tominaga. The role of lysophosphatidylcholine acyltransferase 2 in osteoblastic differentiation of c2c12 cells. FEBS Open Bio, 14:1490-1502, Jul 2024. URL: https://doi.org/10.1002/2211-5463.13845, doi:10.1002/2211-5463.13845. This article has 3 citations and is from a peer-reviewed journal.

5. (korbecki2024phospholipidacyltransferasescharacterization pages 8-9): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

6. (moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5): Christine Moessinger, Lars Kuerschner, Johanna Spandl, Andrej Shevchenko, and Christoph Thiele. Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine. Journal of Biological Chemistry, 286:21330-21339, Jun 2011. URL: https://doi.org/10.1074/jbc.m110.202424, doi:10.1074/jbc.m110.202424. This article has 198 citations and is from a domain leading peer-reviewed journal.

7. (korbecki2024phospholipidacyltransferasescharacterization pages 27-29): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

8. (wang2019phospholipidremodelingin pages 16-17): Bo Wang and Peter Tontonoz. Phospholipid remodeling in physiology and disease. Annual review of physiology, 81:165-188, Feb 2019. URL: https://doi.org/10.1146/annurev-physiol-020518-114444, doi:10.1146/annurev-physiol-020518-114444. This article has 481 citations and is from a highest quality peer-reviewed journal.

## Citations

1. shindou2009recentprogresson pages 4-5
2. tabe2024theroleof pages 3-5
3. korbecki2024phospholipidacyltransferasescharacterization pages 8-9
4. moessinger2011humanlysophosphatidylcholineacyltransferases pages 3-5
5. shindou2009recentprogresson pages 3-4
6. wang2019phospholipidremodelingin pages 16-17
7. wang2019phospholipidremodelingin pages 28-28
8. korbecki2024phospholipidacyltransferasescharacterization pages 27-29
9. https://doi.org/10.1002/2211-5463.13845
10. https://doi.org/10.3390/cancers16112115
11. https://doi.org/10.1038/s41467-017-02732-5
12. https://doi.org/10.1194/jlr.r800035-jlr200
13. https://doi.org/10.1146/annurev-physiol-020518-114444
14. https://doi.org/10.1074/jbc.M110.202424
15. https://doi.org/10.1146/annurev-physiol-020518-114444,
16. https://doi.org/10.1194/jlr.r800035-jlr200,
17. https://doi.org/10.1002/2211-5463.13845,
18. https://doi.org/10.3390/cancers16112115,
19. https://doi.org/10.1074/jbc.m110.202424,